Long-Acting Injectable HIV Treatment Shows Promise In Clinical Trials
Associated Press: J&J, ViiV: 2 injections every month or 2 could control HIV
“Preliminary testing of two long-acting injectable drugs indicates it might be possible to keep HIV at bay indefinitely with injections every month or two. Johnson & Johnson and partner ViiV Healthcare, which specializes in HIV drugs, on Tuesday announced results from the first 32 weeks of the planned 96-week study, which combines one drug from each company…” (Johnson, 11/3).
Reuters: Bi-monthly injection blocks HIV in study from J&J and GSK
“…Paul Stoffels, J&J’s head of pharmaceuticals, said the finding offered a potentially ‘transformational’ way to fight HIV, if the result is confirmed in larger final-stage trials. He believes the combination could be on the market by 2020…” (11/3).